Search:
MS Topics
Diagnosis Classification
Management of MS
Disease Modifying Agents
Imaging in MS
Clinical Trials in MS
Expert Exchange
Calendar of Events
Faculty
MSLeaders Home
Practice Profiles
Pharmacist Center
Nurse Center
Register for Updates
Understanding MS
 
MS Practice Profiles: Therapeutic Choices in Progressing Disease
Sponsored by the Postgraduate Institute for Medicine
Release date: July 2007
Expiration date: July 2008
Estimated time to complete activity: 15 minutes

This educational program is supported through an educational grant from Biogen IDEC and Elan Pharmaceuticals Inc.

The benefits of interferon-beta therapy have been shown to be greater in clinically isolated syndromes and relapsing-remitting MS than in secondary progressive MS. Although these drugs have been shown to be effective, their long-term impact on clinically relevant disability progression is uncertain. There is still a need for more effective treatments, which might include newer agents or combination therapies. This case-based program will examine clinical challenges in the selection of therapeutic agents in progressing MS.

Co-Chair's
Robert J. Fox, MD
Staff Neurologist
The Cleveland Clinic

Nilay Shah, MD
Director, Neurology Division
Riverfront Medical Associates

Author
Randall T. Schapiro, MD
Clinical Professor of Neurology
University of Minnesota
Schapiro Center for Multiple Sclerosis
Minneapolis Clinic of Neurology



Click here for the complete CME information
Resources  |  About Us  |  Contact Us  |  Privacy Policy  |  Disclaimer  |  Editorial & Sponsorship Policy  |  Terms of Use
Search: